Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Sponsor
Ospedale Maggiore Di Trieste
Study ID
NCT04454580
Status
Unknown

Conditions

  • Acute Myeloid Leukemia, Adult
  • Hypomethylating Agents
  • Venetoclax

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    treatment with azacitidine or decitabine in combination with venetoclax

Study Details

This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid leukemia ineligible for intensive chemotherapy

Key Dates

Start date
Aug 1, 2020
Status verified
Sep 2020
Primary completion
Sep 16, 2020
Completion
Sep 30, 2020

Study Design

Enrollment
15 participants (estimated)

Arms

  • Arm: treated patients
    hypomethylating agent (azacitidine or decitabine) in combination with venetoclax

Primary Outcome Measure

Complete response (CR) rate [ Time Frame: every three months after started treatment up to two years ]

Central Contacts

Related Studies